Gateway to Translation (G2T) Webinar - “Discovery of microbiome-based therapeutics: A clinic-first approach in IBD and immune-oncology enabled by precision microbiome profiling.”
| Dates: | 30 April 2024 |
|---|
| Times: | 14:00 - 15:00 |
|---|
| What is it: | Webinar |
|---|
| Organiser: | Faculty of Biology, Medicine and Health |
|---|
| How much: | Free |
|---|
| Who is it for: | University staff, External researchers, Adults, Alumni, Current University students |
|---|
| Speaker: | Dr Mat Robinson |
|---|
|
The “Gateway to Translation” (G2T) webinar series is a joint initiative between the University of Cambridge (Cambridge Academy of Therapeutic Sciences, CATS) and the University of Manchester (Translation Manchester). The aim of these monthly webinars is to stimulate the translation of research into the clinics by educating academics about trends, technologies and research in the commercial sphere and by facilitating collaborations between academia and the medtech, biotech and pharma industry sectors. Recordings from previous webinars are available here.
The next webinar of this series, hosted by Cambridge Academy of Therapeutic Sciences (CATS), will be on Tuesday 30th April 2-3pm (via Zoom). Our guest speaker will be Dr Mat Robinson, Senior Vice President for Research at Microbiotica Ltd. Microbiotica is a Cambridgeshire based company, which identifies gut bacteria linked to phenotype with unprecedented precision in order to discover and develop live bacterial therapeutics and biomarkers from clinical datasets. The name of the talk: “Discovery of microbiome-based therapeutics: A clinic-first approach in IBD and immune-oncology enabled by precision microbiome profiling.”
Please share this with colleagues, or anyone you think may be interested!
Register a place online!
Speaker
Dr Mat Robinson
Role: Senior Vice President for Research
Organisation: Microbiotica Ltd.
Biography: Mat Robinson is SVP Research for Microbiotica, responsible for understanding how the microbes interact with and impact the host, as well as the company’s immuno-oncology program. Mat brings more than 20 years’ research experience across academic and industry.
Travel and Contact Information
